[Inflammatory diseases of the intestines]

C Felley; J Guyot; J Hess; C Mottet; J Delarive; P Michetti

[Inflammatory diseases of the intestines]

Rev Med Suisse. 2006 Jan 18;2(49):191-4, 196-8, 201-3.

[Article in French]

Authors

C Felley¹, J Guyot, J Hess, C Mottet, J Delarive, P Michetti

Affiliation

¹ Service de gastro-entérologie et hépatologie, CHUV, 1011 Lausanne.

PMID: 16493962

Abstract

5-aminosalicylates preparations are not superior to placebo for the maintenance of medically-induced remission in patients with Crohn's disease. We have to reconsider the potential risks associated with inhibition of lymphocyte trafficking since it can induce serious and potentially lethal infections. Infliximab has shown efficacy in active ulcerative colitis.

Publication types

English Abstract
Review

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Antibodies, Monoclonal / therapeutic use
Colitis, Ulcerative / drug therapy*
Colitis, Ulcerative / immunology*
Crohn Disease / drug therapy*
Crohn Disease / immunology*
Gastrointestinal Agents / therapeutic use
Humans
Infliximab
Mesalamine / therapeutic use
Risk Factors

Substances

Adrenal Cortex Hormones
Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Gastrointestinal Agents
Mesalamine
Infliximab